Home LiteratureArticle Details
PMID: 26964730 Published · ppublish English

PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial.

The Journal of clinical endocrinology and metabolism ·Vol. 101 ·No. 4 ·0000-00-00

Fiore Daniela, Gianfrilli Daniele, Giannetta Elisa, Galea Nicola, Panio Giuseppe, di Dato Carla, Pofi Riccardo, Pozza Carlotta, Sbardella Emilia, Carbone Iacopo, Naro Fabio, Lenzi Andrea, Venneri Mary A, Isidori Andrea M

Abstract

This trial provides in-vivo and in-vitro evidence that chronic inhibition of PDE5 in type 2 diabetes regulates miR22 release, SIRT1 expression and epicardial fat, thus improving cardiovascular risk.

Article Info
Journal
The Journal of clinical endocrinology and metabolism
Abbr.
J Clin Endocrinol Metab
ISSN
0021-972X
DOI
10.1210/jc.2015-4252
Published
0000-00-00
Indexed
2016-04-01
Updated
2016-04-01
Language
English
Country/Region
United States
NLM ID
0375362
External Links
PubMed source DOI: 10.1210/jc.2015-4252 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2